Navigation Links
ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
Date:5/5/2008

Conference call scheduled for May 12, 2008 at 1:30 p.m. (Pacific);

simultaneous webcast at http://www.adventrx.com

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that it will host a conference call with simultaneous webcast to discuss first quarter 2008 results on Monday, May 12th, 2008 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Evan M. Levine, Chief Executive Officer and President, and Mark N. K. Bagnall, Chief Financial Officer and Executive Vice President, will host the conference call.

The conference call may be accessed by dialing (888) 215-7013 for domestic callers and (913) 312-1235 for international callers. The webcast will be available live via the Internet by accessing ADVENTRX's web site at http://www.adventrx.com under "Investors". Replays of the webcast will be available for 30 days on ADVENTRX's web site, and a phone replay will be available through May 17, 2008 by dialing (888) 203-1112 and entering the passcode 5439297.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in- licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference
2. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
3. ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference
4. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... Moisture measurement is a necessary process ... paramount to success. Selecting an inappropriate measurement method can cause costly errors, and ... same equipment. Rare or expensive substances are wasted and production may even be ...
(Date:1/23/2017)... ... 2017 , ... "ProRandom is a set of camera tools that allow video editors to integrate ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, ... video footage. ProRandom works by using a virtual camera to create the illusion of ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... Foundation (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the ... (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, ...
(Date:1/23/2017)... ... ... Inn at the Mill”: a story of love and redemption, hope and uncertainty as ... content. , “The Inn at the Mill” is the creation of published author, Lois ... is now living in Berks County on Crow Hill. The inn, the mill ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and ... resources have been developed for use by nutrition educators and influencers within ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017 Varias proteínas ... enal) y el riesgo de diálisis ... pabetalone    Resverlogix Corp. ("Resverlogix" o ... de un ensayo en fase 1 con sede en ... (renal) severa. Los datos demostraron unos resultados importantes en ...
(Date:1/23/2017)... , January 23, 2017 A new Transparency ... Market was valued at US$0.53 bn in 2013 and is ... strong 17.50% CAGR between 2014 and 2022. The title of the ... Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), ...
(Date:1/23/2017)... 2017  ResMed (NYSE : RMD), BMC (Pékin, Chine) et ... aujourd,hui qu,ils se sont mis d,accord sur le règlement ... BMC et 3B seront autorisés à vendre leurs produits ... et ResMed effectuera le paiement de la décision en ... de Floride entre les deux parties. Le règlement n,inclut ...
Breaking Medicine Technology: